AMP
43
3
LOW
42
3
DLTR
52
-8
PLD
35
5
ALLE
14
4
MDT
59
2
PRU
45
5
LNC
35
3
STT
45
-2
F
39
3
MMC
37
-3
CHRW
56
5
BAC
42
3
IFF
45
-2
MAS
40
4
DHR
45
4
GIS
54
4
DFS
64
4
BEN
36
4
EXC
64
4
AMP
43
3
LOW
42
3
DLTR
52
-8
PLD
35
5
ALLE
14
4
MDT
59
2
PRU
45
5
LNC
35
3
STT
45
-2
F
39
3
MMC
37
-3
CHRW
56
5
BAC
42
3
IFF
45
-2
MAS
40
4
DHR
45
4
GIS
54
4
DFS
64
4
BEN
36
4
EXC
64
4
Financhill
Back

TScan Therapeutics 10K Form

Sell
19

TCRX
TScan Therapeutics

Last Price:
$3.06
Seasonality Move:
12.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TCRX News And Ratings

See the #1 stock for the next 7 days that we like better than TCRX

TCRX Financial Statistics

Sales & Book Value

Annual Sales: $21M
Cash Flow: $-29.3M
Price / Cash Flow: 0
Annual Sales: $4.29
Price / Book: 0.76

Profitability

EPS (TTM): -0.96000
Net Income (TTM): $-111.3M
Gross Margin: --
Return on Equity: -60.03%
Return on Assets: -36.44%

TScan Therapeutics Earnings Forecast

Key TScan Therapeutics Financial Ratios

  • The Research & Development expenses have been 418.80% of Revenue.
  • The Interest Expense is -4.21% of Operating Income.
  • The Net Earning history of TCRX is -423.86% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

TScan Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TCRX
Website: tscan.com

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 9.56
Quick Ratio: 9.46

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TCRX Technical Analysis vs Fundamental Analysis

Sell
19
TScan Therapeutics (TCRX) is a Sell

Is TScan Therapeutics a Buy or a Sell?